39例新型冠状病毒肺炎患者的临床特点及疗效分析

doi:10.3969/j.issn.2096-8493.2020.02.008

摘要/Abstract

摘要：

目的探讨新型冠状病毒肺炎(COVID-19)临床特点及治疗效果,为临床诊疗提供依据。方法收集太原市第四人民医院2020年1月21日至3月5日收治的确诊为COVID-19的患者39例作为研究对象。收集并分析研究对象的流行病学特征、人口学特征、临床表现、实验室和胸部CT检查结果、治疗方案及效果评价。结果患者年龄中位数(四分位数)[M(Q₁,Q₃)]为58(37,68)岁,男25例(64.1%),女14例(35.9%);33例(84.6%)患者有明确的与COVID-19患者的接触史。23例(59.0%)为聚集性患者。临床症状以发热最常见[30例(76.9%)],其次为咳嗽[24例(61.5%)]、咳痰[17例(43.6%)]、胸闷及呼吸困难[11例(28.2%)]、乏力[10例(25.6%)]、纳差[4例(10.3%)]、流涕[3例(7.7%)]、鼻塞及咽干咽痛[2例(5.1%)]、肌肉酸痛[1例(2.6%)]。胸部CT扫描提示双侧多发病灶[34例(87.2%)],单侧病灶[5例(12.8%)],阴影多位于肺外带。自发病到咽拭子核酸检测阴转时间的M(Q₁,Q₃)为15(11,19)d。胸部CT扫描所见病变从发病到消散期时间的M(Q₁,Q₃)为17(14,19)d。39例患者全部治愈出院,2~4周后随访无复阳。结论 COVID-19患者多为聚集性发病,症状以发热、咳嗽、咳痰、胸闷、呼吸困难、乏力为主。胸部CT检查有重要的诊断价值。在抗病毒治疗基础上,应用氧疗及适当采用糖皮质激素治疗有助于减轻症状,改善预后。

关键词: 新型冠状病毒肺炎, 诊断,鉴别, 疾病特征, 治疗结果

Abstract:

Objective To investigate the clinical characteristics and therapeutic effects of the coronavirus disease 2019 (COVID-19), and provide evidence for clinical diagnosis and treatment. Methods 39 patients diagnosed with COVID-19 who were admitted to Taiyuan Fourth People’s Hospital from January 21 to March 05,2020 were collected, the epidemiology,demographic characteristics clinical manifestations, laboratory examination,chest CT features, treatment plan and effect evaluation were analyzed. Results Median age (quartile) (M(Q₁,Q₃)) was 58(37,68), 25 males (64.1%),and 14 females (35.9%). 33 cases (84.6%) had a clear exposure history of contact with COVID-19 patients, 23 cases (59.0%) were clustered patients. The most common clinical symptoms were fever (30 cases (76.9%)), followed by cough (24 cases (61.5%)), expectoration (17 cases (43.6%)), chest distress or dyspnea (11 cases (28.2%)), fatigue (10 cases (25.6%)), inappetence (4 cases (10.3%)), runny nose in (3 cases (7.7%)), nasal obstruction and pharyngeal dryness and pharyngalgia (2 cases (5.1%)), and muscle soreness (1 case (2.6%)). CT features showed that bilateral multiple lesions (34 cases, 87.2%) and unilateral lesions (5 cases,12.8%),and the shadows were mostly outside the lung. The median days (quartile) (M(Q₁,Q₃)), from the onset to the negative of the nucleic acid test of the pharyngeal swab negative, were 15(11,19)days. Chest CT features of the lesions from onset to dissipation were 17 (14,19)days. All 39 patients were cured and discharged from hospital, and no recurrence was found in the follow-up after 2 to 4 weeks. Conclusion Most of the COVID-19 patients are cluster cases, and the main symptoms are fever, cough, expectoration, chest distress, dyspnea and fatigue. Chest CT features have important diagnostic value. On the basis of antiviral therapy, oxygen therapy and appropriate glucocorticoid therapy can help reduce symptoms and improve the prognosis.

Key words: Coronavirus disease 2019 (COVID-19), Diagnosis,differential, Disease attributes, Treatment outcome

靳民路, 常蕴青, 齐凤鸣, 关晓岗, 郑冠华, 赵永华, 李震强, 李孝生, 王利芬, 王芳, 白印杰. 39例新型冠状病毒肺炎患者的临床特点及疗效分析[J]. 结核与肺部疾病杂志, 2020, 1(2): 131-135. doi: 10.3969/j.issn.2096-8493.2020.02.008

JIN Min-lu, CHANG Yun-qing, QI Feng-ming, GUAN Xiao-gang, ZHENG Guan-hua, ZHAO Yong-hua, LI Zhen-qiang, LI Xiao-sheng, WANG Li-fen, WANG Fang, BAI Yin-jie. Clinical characteristics and effect analysis of 39 cases of 2019 novel Coronavirus-related pneumonia[J]. Journal of Tuberculosis and Lung Disease, 2020, 1(2): 131-135. doi: 10.3969/j.issn.2096-8493.2020.02.008

参考文献 19

[1]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 2020,395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. URL pmid: 31986264
[2]	Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature, 2020,579(7798):265-269. doi: 10.1038/s41586-020-2008-3. URL pmid: 32015508
[3]	中华人民共和国国家卫生健康委员会办公厅, 中华人民共和国国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第七版). 国卫办医函〔2020〕184号. 2020-03-03.
[4]	Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of 2019 novel coronavirus infection in China. N Engl J Med, 2020,382(18):1708-1720. doi: 10.1056/NEJMoa2002032. URL pmid: 32109013
[5]	李太生, 曹玮, 翁利, 等. 北京协和医院关于“新型冠状病毒感染的肺炎”诊疗建议方案(V2.0). 协和医学杂志, 2020,2(1):12-15. doi: 10.3760/cma.j.issn.0578-1426.2020.03.003.
[6]	中华人民共和国国家卫生健康委员会办公厅. 新型冠状病毒肺炎防控方案(第六版). 国卫办疾控函﹝2020﹞204号. 2020-03-07.
[7]	徐小元, 王广发, 陆海英, 等. SARS临床分期及各期治疗要点的经验总结. 北京大学学报(医学版), 2003,5(35):5-6. doi: 10.3321/j.issn:1671-167X.2003.z1.003.
[8]	黄璐, 韩瑞, 于朋鑫, 等. 新型冠状病毒肺炎不同临床分型间CT和临床表现的相关性研究. 中华放射学杂志, 2020,54(4):300-304. doi: 10.3760/cma.J.issn.10051201.2020.4.0003.
[9]	李洋, 赵立. 阿比多尔抗呼吸道病毒的药理作用与体外和体内疗效研究现状. 中国临床药理学杂志, 2019,17(35):1964-1967. doi: 10.13699/j.cnki.1001-6821.2019.17.035.
[10]	邓国防, 雷建平. 新型冠状病毒肺炎诊治要点浅析. 结核病与肺部健康杂志, 2020,9(1):7-10. doi: 10.3969/j.issn.2095-3755.2020.01.003.
[11]	毛恩强. 浅谈新型冠状病毒肺炎“细胞因子风暴”的防治. 中国中西医结合急救杂志, 2020,27(2):134-136. doi: 10.3969/j.issn.1008-9691.2020.02.002.
[12]	张竞文, 胡欣, 金鹏飞. 新型冠状病毒引起的细胞因子风暴及其药物治疗, 中国药学杂志, 2020,55(5):333-336. doi: 10.11669/cpj.2020.05.001.
[13]	Chang D, Lin M, Wei L, et al. Epidemiologic and clinical chara-cteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA, 2020,323(11):1092-1093. doi: 10.1001/jama.2020.1623. URL pmid: 32031568
[14]	刘荣荣, 朱怡, 吴敏昱, 等. 33例新型冠状病毒感染患者的肺部CT影像学分析. 中华医学杂志, 2020,100(13):1007-1011. doi: 10.3760/cma.j.issn.03762491.2020.0011.
[15]	余辉山, 秦立新, 丁晨宇, 等. 250例新型冠状病毒肺炎高分辨率CT特征分析. 结核病与肺部健康杂志, 2020,9(1):19-24. doi: 10.3969/j.issn.2095-3755.2020.01.006.
[16]	Xiong Y, Sun D, Liu Y, et al. Clinical and highresolution CT features of the COVID-19 infection: comparison of the initial and followup changes. Invest Radiol, 2020,55(6):332-339. doi: 10.1097/RLI.0000000000000674. doi: 10.1097/RLI.0000000000000674 URL pmid: 32134800
[17]	Lei J, Li J, Li X, et al. CT imaging of the 2019 novel coronavirus (2019-ncov) pneumonia. Radiology, 2020,295(1):18. doi: 10.1148/radiol.2020200236. URL pmid: 32003646
[18]	彭鹏, 余辉山, 周新华. 新型冠状病毒肺炎的临床特点与CT诊断价值. 结核病与肺部健康杂志, 2020,9(1):11-15. doi: 10.3969/j.issn.2095-3755.2020.01.004.
[19]	幸海燕, 陈剑鸿. 糖皮质激素治疗新型冠状病毒肺炎的有效性和安全性分析, 中国药业, 2020,29(5):40-43. doi: 10.3969/j.issn.1006-4931.2020.05.008.